絞り込み

16641

広告

「"Ngiow SF "[Author]」の検索結果

36件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

Hidden Caveat of Inducible Cre Recombinase.

TCF-1-Centered Transcriptional Network Drives an Effector versus Exhausted CD8 T Cell-Fate Decision.

TOX transcriptionally and epigenetically programs CD8 T cell exhaustion.

A2AR adenosine signaling suppresses natural killer cell maturation in the tumor microenvironment.

Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells.

Targeting vascular endothelial-cadherin in tumor-associated blood vessels  promotes T cell-mediated immunotherapy.

MAPK signaling and inflammation link melanoma phenotype switching to induction of CD73 during immunotherapy.

Targeting adenosine in BRAF-mutant melanoma reduces tumor growth and metastasis.

G9a drives hypoxia-mediated gene repression for breast cancer cell survival and tumorigenesis.

Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease.

Agonistic CD40 mAb-driven IL-12 reverses resistance to anti-PD1 in a T cell-rich tumor.

Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses.

Co-inhibition of colony stimulating factor-1 receptor and BRAF oncogene in mouse models of BRAF(V600E) melanoma.

Mouse Models of Tumor Immunotherapy.

Combination cancer immunotherapies tailored to the tumour microenvironment.

Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.

TIGIT predominantly regulates the immune response via regulatory T cells.

A threshold level of intratumor CD8+ T cell PD1 expression dictates therapeutic response to anti-PD1.

Natural Killer cell control of mutant melanoma during targeted therapy.

Immunosurveillance and therapy of multiple myeloma are CD226 dependent.

  1. 1
  2. 2
Sort by
※並べ替えは表示に時間がかかります